Rapport Therapeutics (RAPP) – Research Analysts’ Recent Ratings Updates

Rapport Therapeutics (NASDAQ: RAPP) has recently received a number of price target changes and ratings updates:

• 12/9/2025 – Rapport Therapeutics had its price target raised by analysts at HC Wainwright from $34.00 to $40.00. They now have a “buy” rating on the stock.
• 12/8/2025 – Rapport Therapeutics had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $47.00 price target on the stock.
• 12/6/2025 – Rapport Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/19/2025 – Rapport Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $47.00 price target on the stock.
• 11/18/2025 – Rapport Therapeutics was upgraded by analysts at BTIG Research to a “strong-buy” rating.
• 11/7/2025 – Rapport Therapeutics had its price target raised by analysts at Citizens Jmp from $77.00 to $80.00. They now have a “market outperform” rating on the stock.

Insiders Place Their Bets

In other Rapport Therapeutics news, insider David Bredt sold 8,500 shares of Rapport Therapeutics stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $25.79, for a total value of $219,215.00. Following the completion of the transaction, the insider directly owned 409,642 shares of the company’s stock, valued at $10,564,667.18. The trade was a 2.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Wendy B. Young purchased 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 11th. The stock was bought at an average price of $22.60 per share, for a total transaction of $79,100.00. Following the transaction, the director directly owned 9,500 shares of the company’s stock, valued at $214,700. This trade represents a 58.33% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 115,252 shares of company stock worth $3,001,471 in the last 90 days. Company insiders own 13.57% of the company’s stock.

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.